-
Mashup Score: 0Improving Difficult-to-Treat Asthma With Digital Inhaler Adherence Technologies: Are We There Yet? - 5 month(s) ago
Despite remarkable progress in asthma management and targeted therapies, challenges persist in effectively addressing difficult-to-treat asthma patients. Addressing modifiable factors, such as nonadherence, inadequate inhaler technique, and poorly controlled comorbidities such as those that are asthma mimickers, are necessary for adequate asthma control.1 Sanchis et al2 showed that adherence to asthma inhalers falls below that for medications for other chronic conditions and that correct inhaler use technique has remained unacceptably low over the last 40 years, all of which are a call to action in this space.
Source: www.jaci-inpractice.orgCategories: Allergy-Immunology, Latest HeadlinesTweet
-
Mashup Score: 0Long-Term Cost-Effectiveness of Digital Inhaler Adherence Technologies in Difficult-to-Treat Asthma - 6 month(s) ago
Digital inhalers can monitor inhaler usage, support difficult-to-treat asthma management, and inform step-up treatment decisions yet their economic value is unknown, hampering wide-scale implementation.
Source: www.jaci-inpractice.orgCategories: Latest Headlines, PulmonologyTweet
-
Mashup Score: 5New Stock Epinephrine and Stock Inhaler Toolkits - 7 month(s) ago
New Stock Epinephrine and Stock Inhaler Toolkits Improve Safety of Students with Anaphylaxis and Asthma
Source: www.aaaai.orgCategories: Allergy-Immunology, Latest HeadlinesTweet
-
Mashup Score: 0Long-term cost-effectiveness of digital inhaler adherence technologies in difficult-to-treat asthma - 9 month(s) ago
Digital inhalers can monitor inhaler usage, support difficult-to-treat asthma management and inform step-up treatment decisions yet their economic val…
Source: www.sciencedirect.comCategories: Latest Headlines, PulmonologyTweet
-
Mashup Score: 0
Several states in the United States (U.S.) have laws permitting stock inhalers, including short-acting beta-agonist inhalers, such as albuterol, and spacers to be prescribed to, dispensed to, and stocked in schools for use in students in respiratory distress, based on a protocol. This survey study a …
Source: PubMedCategories: Latest Headlines, PulmonologyTweet
-
Mashup Score: 0
A novel, once-daily, fixed-dose combination of mometasone furoate/indacaterol acetate/glycopyrronium bromide (MF/IND/GLY) delivered via Breezhaler® is the first inhaled corticosteroid/long-acting ꞵ2-agonist/long-acting muscarinic antagonist (ICS/LABA/LAMA) therapy approved for the maintenance treatment of asthma in adults inadequately controlled on ICS/LABA combination. In patients with asthma…
Source: Respiratory MedicineCategories: Latest Headlines, PulmonologyTweet
-
Mashup Score: 0Pharmalittle: Sanofi cuts price on a popular insulin by 78%; Califf criticizes insurers for doing too little on drug research - 1 year(s) ago
FDA Commissioner Robert Califf wants private insurers to chip in on doing post-approval clinical research on drugs.
Source: STATCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 3
“This could make it easier for generic firms to circumvent device patents on inhalers and bring their products to the market earlier,” researcher William Feldman said.
Source: STATCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0Evaluating Inhaler Education Interventions for Hospitalized Children with Asthma: A Randomized Controlled Trial - 1 year(s) ago
Most children with asthma have poor inhaler technique, with detrimental morbidity effects. Guidelines recommend clinicians provide inhaler education at every opportunity, yet resources are limited. A low-cost, technology-based intervention—Virtual Teach-to-Goal (V-TTG)—was developed to deliver tailored inhaler technique education with high fidelity.
Categories: Latest Headlines, PulmonologyTweet
-
Mashup Score: 4
The FDA approved a pressurized metered-dose inhaler with a fixed-dose combination of albuterol and budesonide for use as rescue medication among patients with asthma aged 18 years and older, according to a manufacturer-issued press release.According to the release, the FDA approved albuterol/budesonide (Airsupra; Avillion, AstraZeneca), previously known as PT027, in this patient population for
Source: www.healio.comCategories: Latest Headlines, PulmonologyTweet
In Current Issue (FREE)! Improving Difficult-to- #Treat #Asthma With #Digital #Inhaler #Adherence #Technologies: Are We There Yet? https://t.co/UfFapAV63w